TY - JOUR
T1 - The insulin-like growth factor-I receptor as an oncogene
AU - Werner, Haim
AU - Bruchim, Ilan
N1 - Funding Information:
Work in the laboratory of HW is supported by grants from the US–Israel Binational Science Foundation (Grant 2003341), Insulin-Dependent Diabetes Trust (United Kingdom), and Israel Cancer Research Fund (New York). IB wishes to thank the Israel Cancer Research Fund (Montreal, Canada) for their generous support.
PY - 2009/5
Y1 - 2009/5
N2 - The insulin-like growth factor-I receptor (IGF-IR) mediates the biological actions of both IGF-I and IGF-II. The IGF-IR is expressed in most transformed cells, where it displays potent antiapoptotic, cell-survival, and transforming activities. IGF-IR expression is a fundamental prerequisite for the acquisition of a malignant phenotype, as suggested by the finding that IGF-IR-null cells (derived from IGF-IR knock-out embryos) are unable to undergo transformation when exposed to cellular or viral oncogenes. This review article will focus on the underlying molecular mechanisms that are responsible for the normal, physiological control of IGF-IR gene expression, as well as the cellular pathways that underlie its aberrant expression in cancer. Examples from the clinics will be presented, including a description of how the IGF system is involved in breast, prostate, pediatric, and gynecological cancers. Finally, current attempts to target the IGF-IR as a therapeutic approach will be described.
AB - The insulin-like growth factor-I receptor (IGF-IR) mediates the biological actions of both IGF-I and IGF-II. The IGF-IR is expressed in most transformed cells, where it displays potent antiapoptotic, cell-survival, and transforming activities. IGF-IR expression is a fundamental prerequisite for the acquisition of a malignant phenotype, as suggested by the finding that IGF-IR-null cells (derived from IGF-IR knock-out embryos) are unable to undergo transformation when exposed to cellular or viral oncogenes. This review article will focus on the underlying molecular mechanisms that are responsible for the normal, physiological control of IGF-IR gene expression, as well as the cellular pathways that underlie its aberrant expression in cancer. Examples from the clinics will be presented, including a description of how the IGF system is involved in breast, prostate, pediatric, and gynecological cancers. Finally, current attempts to target the IGF-IR as a therapeutic approach will be described.
KW - Cancer
KW - Gene expression
KW - IGF-I receptor
KW - Insulin-like growth factor-I (IGF-I)
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=68149103024&partnerID=8YFLogxK
U2 - 10.1080/13813450902783106
DO - 10.1080/13813450902783106
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:68149103024
SN - 1381-3455
VL - 115
SP - 58
EP - 71
JO - Archives of Physiology and Biochemistry
JF - Archives of Physiology and Biochemistry
IS - 2
ER -